SCHEMBL16618194

SCHEMBL16618194

COC(=O)[C@@H]1CCCC[C@H]1C(=O)Cc1ccc(Br)cc1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 1/20 0.53
HTT P42858 1/20 0.53
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
HPGD P15428 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.43
EPHX2 P34913 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
LMNA P02545 1/20 0.41
SLC6A2 P23975 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16618196 1.00 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL16624856 0.84 KMT2A (0.43) SMN1; SMN2ALDH1A1HTTKMT2AEPHX2
SCHEMBL16618143 0.83 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL16618142 0.83 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL18440290 0.82 SLC6A2 (0.48) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL16617332 0.82 MEN1 (0.47) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL16624855 0.79 SLC6A2 (0.41) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL1748035 0.78 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL1748036 0.78 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL1748037 0.78 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055314-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-09-12 EP disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
WO-2015054089-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SMN1; SMN2 4512/4885ALDH1A1 4582/4885HTT 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.